A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)

高磷血症 医学 磷酸盐粘合剂 内科学 透析 重症监护医学 机制(生物学) 随机对照试验 磷酸盐 肾脏疾病 化学 生物化学 认识论 哲学
作者
Pablo E. Pérgola,David P. Rosenbaum,Yang� Yang,Glenn M. Chertow
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:32 (6): 1465-1473 被引量:80
标识
DOI:10.1681/asn.2020101398
摘要

Significance Statement In patients receiving maintenance dialysis, strategies for managing hyperphosphatemia are only moderately effective. In this 4-week randomized trial involving 236 patients experiencing hyperphosphatemia despite phosphate binder use, tenapanor (a small molecule that inhibits paracellular phosphate absorption) significantly reduced serum phosphorus concentration from baseline, compared with placebo, when used with phosphate binders as a dual-mechanism treatment. A significantly larger proportion of patients randomized to tenapanor plus binder achieved a serum phosphorus concentration <5.5 mg/dl at all time points compared with placebo plus binder. Few patients discontinued tenapanor because of diarrhea (the most frequently reported adverse event) or other adverse events. These findings indicate that evaluation of long-term safety and efficacy of this dual-mechanism treatment of hyperphosphatemia is merited. Background Hyperphosphatemia is associated with cardiovascular morbidity and mortality in patients receiving maintenance dialysis. It is unknown whether combining two therapies with different mechanisms of action—tenapanor, an inhibitor of paracellular phosphate absorption, and phosphate binders—is safe and effective for the management of hyperphosphatemia in patients receiving maintenance dialysis. Methods This double-blind phase 3 trial enrolled 236 patients undergoing maintenance dialysis with hyperphosphatemia (defined in this trial as serum phosphorus 5.5–10 mg/dl inclusive) despite receiving phosphate binder therapy (sevelamer, nonsevelamer, sevelamer plus nonsevelamer, or multiple nonsevelamer binders). These participants were randomly assigned to receive oral tenapanor 30 mg twice daily or placebo for 4 weeks. The primary efficacy end point was the change in serum phosphorus concentration from baseline to week 4. Results Of the 236 randomized patients, 235 (99.6%) were included in the full analysis set; this included 116 in the tenapanor plus binder group and 119 in the placebo plus binder group. A total of 228 patients (96.6%) completed the 4-week treatment period. In the full analysis set (mean age 54.5 years, 40.9% women), patients treated with tenapanor plus binder achieved a larger mean change in serum phosphorus concentration from baseline to week 4 compared with placebo plus binder (−0.84 versus −0.19 mg/dl, P <0.001). Diarrhea was the most commonly reported adverse event, resulting in study drug discontinuation in four of 119 (3.4%) and two of 116 (1.7%) patients receiving tenapanor plus binder or placebo plus binder, respectively. Conclusions A dual-mechanism treatment using both tenapanor and phosphate binders improved control of hyperphosphatemia in patients undergoing maintenance dialysis compared with phosphate binders alone. Clinical Trial registry name and registration number: AMPLIFY, NCT03824587
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HAOna完成签到 ,获得积分10
2秒前
杏宁十完成签到 ,获得积分10
2秒前
Maestro_S的应助被Vincent采纳,获得10
5秒前
lichunrong完成签到,获得积分10
5秒前
我不到啊完成签到 ,获得积分10
8秒前
9秒前
朴实无招完成签到,获得积分10
10秒前
随风飘远完成签到 ,获得积分10
14秒前
14秒前
丸子完成签到 ,获得积分10
15秒前
桃子完成签到 ,获得积分10
15秒前
lei.qin完成签到 ,获得积分10
16秒前
cyan完成签到 ,获得积分10
17秒前
LQY完成签到 ,获得积分10
22秒前
态度完成签到 ,获得积分10
23秒前
24秒前
等待念之完成签到,获得积分10
24秒前
赘婿的应助被tianmengkui采纳,获得10
28秒前
29秒前
小呱完成签到 ,获得积分10
30秒前
璇璇完成签到 ,获得积分10
32秒前
拓跋幻枫完成签到,获得积分10
35秒前
35秒前
兰彻完成签到,获得积分10
35秒前
老六完成签到 ,获得积分10
36秒前
勋章完成签到 ,获得积分10
36秒前
唐陌完成签到 ,获得积分10
38秒前
鱼鱼鱼鱼完成签到 ,获得积分10
39秒前
危机的棒棒糖完成签到,获得积分10
41秒前
韭黄完成签到,获得积分10
44秒前
45秒前
tianmengkui完成签到,获得积分10
47秒前
macrossfev完成签到,获得积分10
49秒前
53秒前
韭菜完成签到,获得积分10
53秒前
情怀的应助被tianmengkui采纳,获得10
53秒前
Willwzh完成签到,获得积分10
53秒前
yx完成签到 ,获得积分10
56秒前
58秒前
Sun1c7完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190360
求助须知:如何正确求助?哪些是违规求助? 9577423
关于积分的说明 21852492
捐赠科研通 7788942
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482995